In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.
While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.
In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.
Overall, semaglutide prescribing during pregnancy was not associated with significant differences in maternal or newborn outcomes studied in this routine care setting.
In a small subset with 90-day follow-up weights, oral Wegovy was associated with greater early weight loss than Foundayo; comparative safety findings remain exploratory.
Across a large observational cohort, higher attained dose was associated with lower later incidence of several neuropsychiatric diagnoses, while dementia rates did not differ significantly.
Among 58,618 semaglutide or tirzepatide initiators who lost at least 5% of body weight, 14.3% regained at least five percentage points by one year. Regain sometimes occurred despite continued treatment documentation and coincided with inflammatory signals and higher cardiovascular event rates, but medication use and causality could not be confirmed.
Clinical-note surveillance found rapidly growing use of products purported to contain retatrutide outside clinical trials. Compounded users lost 7.2% at six to twelve months versus 15.5% in trial participants, while early cardiovascular findings remain preliminary.